Safety Study of Abatacept to Treat Rheumatoid Arthritis (A)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to compare the incidence rates of infection among patients with rheumatoid arthritis who are treated with abatacept and those who are treated with other anti-rheumatic medications
Infections, specifically hospitalized infection, hospitalized pneumonia, hospitalized and/or IV treated pneumonia, tuberculosis, herpes zoster, and opportunistic infection [ Time Frame: Every four months throughout the study ]
Secondary Outcome Measures
Anaphylactic reactions [ Time Frame: Every four months throughout the study ]
Multiple sclerosis, lupus, and psoriasis [ Time Frame: Every four months throughout the study ]
Concomitant biologic use [ Time Frame: Every four months throughout the study ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
Child, Adult, Senior
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Diagnosis of rheumatoid arthritis
Claims indicating infusion, injection, or dispensing of abatacept, a DMARD, or a BDM
Age 18 years or older at the time of drug initiation
Enrollment in the health plan at least 6 continuous months leading up to the time of study drug initiation
Below 18 years of age at the time of BDM or DMARD initiation
Lacking six months of continuous enrollment prior to the initiation of one of the study drugs